Interestingly, the arginine vasopressin receptor, AVPR1A, was also found to be downregulated in thyroid cancer and associated with progression-free survival, while it was upregulated in castration-resistant prostate cancer with an antitumoral effect of a selective AVPR1A antagonist [14,57]. The gene discussed is AVPR1A; the disease is thyroid gland carcinoma.